^
    Back
    Association details:
    Biomarker:NUSAP1 overexpression
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Int J Biol Sci.
    Title:

    Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response

    Published date:
    10/02/2023
    Excerpt:
    Notably, patients with melanoma, lung, and kidney cancer with high NUSAP1 expression levels have shorter survival times and lower immunotherapy response rates.
    DOI:
    10.7150/ijbs.80017